Drugs /

ino-9012

Back to Drugs List

Overview

NCI Definition [1]:
A plasmid DNA vaccine encoding the human pro-inflammatory cytokine interleukin-12 (IL-12) with potential immunoactivating activity. Upon intramuscular delivery by electroporation of rocakinogene sifuplasmid, IL-12 is translated in cells and activates the immune system by promoting the activation of natural killer cells (NK cells), inducing secretion of interferon-gamma and promoting cytotoxic T-cell responses against tumor cells. This may result in both immune-mediated tumor cell death and the inhibition of tumor cell proliferation.

Clinical Trials

View Clinical Trials for ino-9012

Ino-9012 has been investigated in 4 clinical trials, of which 4 are open and 0 are closed. Of the trials investigating ino-9012, 2 are phase 1 (2 open) and 2 are phase 1/phase 2 (2 open).

ER Negative, ER No Expression, and HER2 Deficient Expression are the most frequent biomarker inclusion criteria for ino-9012 clinical trials.

Breast carcinoma, glioblastoma, and hepatocellular carcinoma are the most common diseases being investigated in ino-9012 clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Ino-9012
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating ino-9012 and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
rocakinogene sifuplasmid, rocakinogene sifuplasmid, dna plasmid encoding interleukin-12 ino-9012
NCIT ID [1]:
C116709

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.